Should clot composition affect choice of endovascular therapy?

被引：43
作者：
Mehta, Brijesh P. [4 ]
Nogueira, Raul G. [1 ,2 ,3 ]
机构：
[1] Emory Univ, Grady Hosp, Dept Neurol, Atlanta, GA 30322 USA
[2] Emory Univ, Grady Hosp, Dept Neurosurg, Atlanta, GA 30322 USA
[3] Emory Univ, Grady Hosp, Dept Radiol, Atlanta, GA 30322 USA
[4] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA
来源：
NEUROLOGY | 2012年 / 79卷 / 13期
关键词：
TISSUE-PLASMINOGEN-ACTIVATOR; ACUTE ISCHEMIC-STROKE; THROMBOLYSIS; THROMBI; TRIAL; ASSOCIATION; ARTERIES;
D O I：
10.1212/WNL.0b013e3182695859
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Endovascular therapy has become a promising alternative for patients who are ineligible for IV thrombolysis or for whom it has failed. Greater knowledge about the composition of thromboembolic material underlying the vascular occlusion in stroke patients may provide the means for improving existing endovascular therapies and developing new treatment strategies. The objective of this article is to provide a review of clinical and experimental animal studies on the histology, imaging correlation, and ultrastructure of thromboemboli retrieved during acute ischemic stroke. Neurology (R) 2012; 79 (Suppl 1): S63-S67
引用
收藏
页码：S63 / S67
页数：5
相关论文
共 26 条
  • [1] Guidelines for the early management of patients with ischemic stroke - A scientific statement from the Stroke Council of the American Stroke Association
    Adams, HP
    Adams, RJ
    Brott, T
    del Zoppo, GJ
    Furlan, A
    Goldstein, LB
    Grubb, RL
    Higashida, R
    Kidwell, C
    Kwiatkowski, TG
    Marler, JR
    Hademenos, GJ
    [J]. STROKE, 2003, 34 (04) : 1056 - 1083
  • [2] *AM HEART ASS, HEART STROK FACTS 20
  • [3] Heparin and oral anticoagulants in the treatment of brain ischemia
    Chaves, CJ
    Caplan, LR
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2000, 173 (01) : 3 - 9
  • [4] Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial
    Clark, WM
    Wissman, S
    Albers, GW
    Jhamandas, JH
    Madden, KP
    Hamilton, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21): : 2019 - 2026
  • [5] The Food and Drug Administration medical device review process -: Clearance of a clot retriever for use in ischemic stroke
    Felten, RP
    Ogden, NRP
    Peña, C
    Provost, MC
    Schlosser, MJ
    Witten, CM
    [J]. STROKE, 2005, 36 (02) : 404 - 406
  • [6] CT VISUALIZATION OF INTRACRANIAL ARTERIAL THROMBOEMBOLISM
    GACS, G
    FOX, AJ
    BARNETT, HJM
    VINUELA, F
    [J]. STROKE, 1983, 14 (05) : 756 - 762
  • [7] MERCI 1 - A phase 1 study of mechanical embolus removal in cerebral ischemia
    Gobin, YP
    Starkman, S
    Duckwiler, GR
    Grobelny, T
    Kidwell, CS
    Jahan, R
    Pile-Spellman, J
    Segal, A
    Vinuela, F
    Saver, JL
    [J]. STROKE, 2004, 35 (12) : 2848 - 2853
  • [8] DIFFERENTIAL SENSITIVITY OF ERYTHROCYTE-RICH AND PLATELET-RICH ARTERIAL THROMBI TO LYSIS WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR - A POSSIBLE EXPLANATION FOR RESISTANCE TO CORONARY THROMBOLYSIS
    JANG, IK
    GOLD, HK
    ZISKIND, AA
    FALLON, JT
    HOLT, RE
    LEINBACH, RC
    MAY, JW
    COLLEN, D
    [J]. CIRCULATION, 1989, 79 (04) : 920 - 928
  • [9] Early recanalization rates and clinical outcomes in patients with tandem internal carotid artery/middle cerebral artery occlusion and isolated middle cerebral artery occlusion
    Kim, YS
    Garami, Z
    Mikulik, R
    Molina, CA
    Alexandrov, AV
    [J]. STROKE, 2005, 36 (04) : 869 - 871
  • [10] Kirchhof K, 2004, ROFO-FORTSCHR RONTG, V176, P98
123